“Pemphigus Vulgaris Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Pemphigus Vulgaris market. A detailed picture of the Pemphigus Vulgaris pipeline landscape is provided, which includes the disease overview and Pemphigus Vulgaris treatment guidelines. The assessment part of the report embraces in-depth Pemphigus Vulgaris commercial assessment and clinical assessment of the Pemphigus Vulgaris pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pemphigus Vulgaris collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Pemphigus Vulgaris (PV) is a rare, potentially fatal, autoimmune and intraepithelial disease characterized by flaccid blisters and erosions of the skin, and also mucous membrane and histologically by acantholysis. It is mediated by circulating desmoglein-reactive autoantibodies, directed against keratinocyte cell surfaces.

Pemphigus Vulgaris Overview

“Pemphigus Vulgaris Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Pemphigus Vulgaris market. A detailed picture of the Pemphigus Vulgaris pipeline landscape is provided, which includes the disease overview and Pemphigus Vulgaris treatment guidelines. The assessment part of the report embraces in-depth Pemphigus Vulgaris commercial assessment and clinical assessment of the Pemphigus Vulgaris pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pemphigus Vulgaris collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Pemphigus Vulgaris Analytical Perspective by DelveInsight

In-depth Pemphigus Vulgaris Commercial Assessment of products

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

Pemphigus Vulgaris Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Report key facts:-

1. The annual frequency of PV has been reported between 0.76 and 16.1 per million population, depending on the geographical area and the ethnicity. (Didona et al.)

2. In a recent analysis on the US population, an overall standardized point prevalence of 5.2 cases per 100,000 adults has been reported. (Wertenteil et al.)

3. Among the EU5 countries, Germany has the highest prevalent population of PV, followed by France. Spain has the lowest prevalent cases.

“The increase in Market size is a direct consequence of increasing prevalent population of Pemphigus Vulgaris (PV) patients in the 7MM”